The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by PAR-22-071.
Who won it before
12 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,581,923 in first-year total cost, median $603,171.
Most frequent study sections
- Special Emphasis Panel[ZRG1 IMST-A (55)]4
- Special Emphasis Panel[ZRG1 IMST-M (55)]4
- Special Emphasis Panel[ZRG1 IMST-U (55)]4
Most frequent institutions
- EMORY UNIVERSITY1
- FRED HUTCHINSON CANCER RESEARCH CENTER1
- MASSACHUSETTS GENERAL HOSPITAL1
- PURDUE UNIVERSITY1
- STANFORD UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Toward translation of a plant virus-based in situ vaccination nanotechnology1R01CA274640-01 | FIERING, STEVENRANJAN, ASHISHSTEINMETZ, NICOLE FRANZISKA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $649,918 | ZRG1 |
| 2022 | Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy1R01CA257842-01A1 | CHOW, DIANA S-L.LI, CHUNYANG, PEIYING | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $642,984 | ZRG1 |
| 2022 | Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC1R01CA274677-01 | KANNAN, RAGHURAMAN | UNIVERSITY OF MISSOURI-COLUMBIA, MO | $622,068 | ZRG1 |
| 2022 | Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma1R01CA274675-01 | WILSON, JOHN TANNER | VANDERBILT UNIVERSITY, TN | $604,335 | ZRG1 |
| 2021 | High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer1R01CA264363-01 | CASTRO, CESAR MLEE, HAKHO | MASSACHUSETTS GENERAL HOSPITAL, MA | $662,338 | ZRG1 |
| 2021 | TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION1R01CA264488-01 | KABANOV, ALEXANDER V | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $613,059 | ZRG1 |
| 2021 | Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer1R01CA258737-01 | KRON, STEPHEN J.YEO, YOON | PURDUE UNIVERSITY, IN | $602,006 | ZRG1 |
| 2021 | Rapid and affordable magneto-nanosensors for ctDNA-guided lung cancer management1R01CA257843-01A1 | WANG, SHAN X. | STANFORD UNIVERSITY, CA | $573,461 | ZRG1 |
| 2021 | Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer1R01CA257851-01 | KIM, WILLIAM Y.LI, ZIBOXIE, JIN | UNIVERSITY OF GEORGIA, GA | $552,591 | ZRG1 |
| 2021 | Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis1R01CA257861-01 | YANG, LILY | EMORY UNIVERSITY, GA | $542,085 | ZRG1 |
| 2021 | Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy1R01CA257837-01 | KWON, GLEN S. | UNIVERSITY OF WISCONSIN-MADISON, WI | $347,945 | ZRG1 |
| 2021 | Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing1R01CA263524-01 | STEPHAN, MATTHIAS | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $169,133 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.